Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
g3nFDnHj5PhstnaK
